Get the Stockscreener App
2.04
4.67%
-0.10
Pre-market:
2.05
0.010
+0.49%
Immunitybio Inc stock is traded at $2.04, with a volume of 12.00M.
It is down -4.67% in the last 24 hours and down -13.56% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.14
Open:
$2.12
24h Volume:
12.00M
Relative Volume:
1.11
Market Cap:
$2.01B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.1031
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
-10.13%
1M Performance:
-13.56%
6M Performance:
-24.44%
1Y Performance:
-26.62%
1-Day Range:
$2.03
$2.14
1-Week Range:
$2.03
$2.25
52-Week Range:
$1.83
$4.27
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.04 | 2.11B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.78 | 117.45B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.50 | 82.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.82 | 52.92B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.45 | 52.02B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.34 | 37.94B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of "100 Most Influential People in Oncology in 2025" - Yahoo Finance
Immunitybio amends sale agreement with Jefferies LLCSEC filing - marketscreener.com
ImmunityBio Signs Amendment to Open Market Sale Agreement With Jefferies - TradingView — Track All Markets
ImmunityBio Inc Stock Analysis and ForecastShort-Term Trading Alerts & Outstanding Trading Tips - earlytimes.in
ImmunityBio, Inc.Common Stock (NQ: IBRX - FinancialContent
Latest IBRX Insights: Stock Movement and Corporate Developments - StocksToTrade
ImmunityBio (NASDAQ:IBRX) Shares Down 5.1%Here's What Happened - MarketBeat
3 Growth Companies With Insider Ownership Up To 37% - simplywall.st
ImmunityBio Sees Shift Amid Market Turbulence - timothysykes.com
Analyzing the Surge: ImmunityBio’s Market Impact - StocksToTrade
ImmunityBio (NASDAQ:IBRX) Stock Price Up 8.9%Should You Buy? - MarketBeat
How Investors May Respond To ImmunityBio (IBRX) Bladder Cancer Milestone And EMA Backing For ANKTIVA - Sahm
Can ImmunityBio Inc. stock sustain institutional interestJuly 2025 Snapshot & Fast Moving Trade Plans - ulpravda.ru
Is ImmunityBio Inc. stock vulnerable to regulatory risksQuarterly Profit Review & Free Long-Term Investment Growth Plans - Bölüm Sonu Canavarı
Rate Hike: Can ImmunityBio Inc. (26CA) stock stage a strong rebound this quarterWeekly Profit Analysis & Weekly Consistent Profit Watchlists - moha.gov.vn
Can ImmunityBio Inc. (26CA) stock withstand sector downturnsRate Hike & Weekly Momentum Stock Picks - Улправда
Can ImmunityBio Inc. stock beat market expectations this quarterQuarterly Market Review & Fast Entry High Yield Stock Tips - DonanımHaber
Why hedge funds are buying ImmunityBio Inc. stockJuly 2025 Momentum & Weekly Momentum Stock Picks - DonanımHaber
Stop Loss: Why ImmunityBio Inc. stock could benefit from AI revolutionTrade Volume Report & Fast Gain Stock Tips - Улправда
ImmunityBio: Anktiva Revenue Will Ramp, But Competitive Risks Remain - Seeking Alpha
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment - Yahoo Finance
ImmunityBio, Moderna among winners of EU drug recommendations this week - MSN
Is ImmunityBio, Inc. (IBRX) the best NASDAQ stock under $10 to buy? - MSN
Is ImmunityBio, Inc. (IBRX) The Best NASDAQ Stock Under $10 to Buy? - Insider Monkey
Jefferies Lifts ImmunityBio Inc. (IBRX) Price Target Following Anktiva European Expansion - Yahoo Finance
ImmunityBio’s HCW9218 study completion: A potential game-changer for pancreatic cancer treatment - MSN
[Form 4] ImmunityBio, Inc. Insider Trading Activity - Stock Titan
ImmunityBio reports encouraging 3-year bladder cancer treatment data - The Pharma Letter
ImmunityBio (NASDAQ: IBRX) director files insider report with no holdings - Stock Titan
ImmunityBio Reports Strong Long-Term Survival Data For Anktiva In Bladder Cancer Study - Sahm
ImmunityBio Reports 96% Three-Year Bladder Cancer Survival With Anktiva Plus BCG - marketscreener.com
ImmunityBio reports promising 3-year bladder cancer treatment data - Investing.com India
ImmunityBio reports promising 3-year bladder cancer treatment data By Investing.com - Investing.com Nigeria
ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer - Investing News Network
Anktiva® with BCG demonstrates 96% survival from bladder cancer - marketscreener.com
ImmunityBio appoints Bruce Wendel to board - MSN
Assessing ImmunityBio (IBRX) Valuation After EMA Backs Anktiva for BCG‑Unresponsive Bladder Cancer - simplywall.st
ImmunityBio Appoints Bruce Wendel to Board - TipRanks
ImmunityBio, Inc. Appoints Bruce Wendel to the Board, Effective December 12, 2025 - marketscreener.com
[8-K] ImmunityBio, Inc. Reports Material Event | IBRX SEC FilingForm 8-K - Stock Titan
ImmunityBio (NASDAQ:IBRX) Stock Price Down 7.8%Here's Why - MarketBeat
ImmunityBio (IBRX) Stock in Focus on Dec. 15, 2025: EMA’s ANKTIVA Nod, Analyst Targets, and What Comes Next - ts2.tech
Can ImmunityBio Inoculate Its Future With Regulatory Wins? - RTTNews
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies - MSN
ImmunityBio’s HCW9218 Study Completion: A Potential Game-Changer for Pancreatic Cancer Treatment - TipRanks
Should EMA’s Conditional Nod for ANKTIVA in High-Risk Bladder Cancer Require Action From ImmunityBio (IBRX) Investors? - Yahoo Finance
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
ImmunityBio (NASDAQ:IBRX) Shares Gap UpHere's Why - MarketBeat
Has The Recent ImmunityBio Share Price Rebound Created An Opportunity In 2025? - Sahm
ImmunityBio (IBRX) climbs 7.76% on Europe expansion - MSN
ImmunityBio (IBRX) Climbs 7.76% on Europe Expansion - Insider Monkey
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):